165 Apremilast, an oral phosphodiesterase-4 inhibitor, is associated with long-term (156-week) improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in subjects with psoriatic arthritis: pooled results from three phase III randomised controlled trials

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 57; no. suppl_3
Main Authors Mease, Philip J, Marzo-Ortega, Helena, Poder, Airi, Van den Bosch, Filip, Wollenhaupt, Jurgen, Lespessailles, Eric, Teng, Lichen, Hall, Stephen
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.04.2018
Oxford Publishing Limited (England)
Subjects
Ankylosing spondylitis
Arthritis
Phosphodiesterase
Psoriatic arthritis
Spondylitis
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Conference Proceeding-1
SourceType-Scholarly Journals-1
content type line 14
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/key075.389